Chemed (NYSE:CHE) Hits New 12-Month High After Strong Earnings

Chemed Corporation (NYSE:CHE)’s share price hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $519.05 and last traded at $514.9440, with a volume of 3626 shares trading hands. The stock had previously closed at $509.34.

The company reported $6.06 EPS for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. The firm had revenue of $673.25 million during the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 30.64%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm earned $4.27 EPS. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS.

Chemed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is presently 13.08%.

Trending Headlines about Chemed

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Quarterly results exceeded expectations. Adjusted EPS was $6.06, ahead of the $5.55–$5.60 analyst consensus and up 41.9% from $4.27 a year earlier. Revenue rose 8.8% to $673.3 million, surpassing estimates of approximately $665 million. Chemed Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: VITAS drove the strongest growth. Net patient revenue increased 11.9% to $443.3 million, while average daily census rose 6.1% and admissions grew 9.0%. VITAS adjusted EBITDA increased 20.6%, with its margin expanding by 196 basis points to 18.2%. Chemed Reports Second-Quarter 2026 Results
• Positive Sentiment: Full-year earnings guidance was raised. Chemed now expects 2026 adjusted EPS of $25.00 to $25.75, above the prior outlook and the roughly $24.01 consensus estimate. Management attributed the increase primarily to VITAS outperformance, while maintaining its Roto-Rooter outlook. Chemed Raises 2026 Guidance
• Positive Sentiment: Share repurchases provided additional support. Chemed bought back approximately 210,000 shares for $89.8 million during the quarter, signaling confidence in the business and reducing shares outstanding.
• Neutral Sentiment: Roto-Rooter performance was mixed. Revenue rose 3.3% to $229.9 million, but net income and adjusted EBITDA were essentially flat, while the EBITDA margin declined 77 basis points to 21.1%. This limits the segment’s contribution relative to VITAS.
• Negative Sentiment: Insider activity was unfavorable. Company insiders reported five sales and no purchases over the past six months. The activity may temper sentiment, although it is less significant than the earnings beat and raised guidance.

Wall Street Analyst Weigh In

CHE has been the topic of several analyst reports. Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wall Street Zen downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Monday, June 8th. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research note on Wednesday. Royal Bank Of Canada boosted their price objective on shares of Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Finally, Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $480.25.

Insider Activity at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer directly owned 90,219 shares in the company, valued at $37,993,927.47. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the sale, the director directly owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. This trade represents a 22.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.33% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CHE. Monetary Solutions Ltd purchased a new position in Chemed during the 4th quarter valued at about $25,000. Los Angeles Capital Management LLC bought a new position in shares of Chemed during the fourth quarter valued at approximately $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Chemed during the fourth quarter valued at approximately $27,000. Versant Capital Management Inc increased its holdings in Chemed by 7,500.0% during the second quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after buying an additional 75 shares during the period. Finally, Global Retirement Partners LLC increased its holdings in Chemed by 200.0% during the fourth quarter. Global Retirement Partners LLC now owns 87 shares of the company’s stock valued at $37,000 after buying an additional 58 shares during the period. 95.85% of the stock is currently owned by institutional investors.

Chemed Stock Up 3.9%

The company has a market cap of $7.13 billion, a P/E ratio of 27.00, a P/E/G ratio of 1.91 and a beta of 0.52. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average is $463.37 and its 200 day moving average is $435.25.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.